Get the Stockscreener App
21.21
1.16%
0.2394
Beta Bionics Inc stock is traded at $21.21, with a volume of 87,444.
It is up +1.16% in the last 24 hours and down -6.76% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product include the iLet Bionic Pancreas (iLet). The Company operates as single segment, focused on the development, manufacture and sale of the iLet.
See More
Previous Close:
$20.97
Open:
$21.04
24h Volume:
87,444
Relative Volume:
1.00
Market Cap:
$889.87M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.98%
1M Performance:
-6.76%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$20.02
$21.41
1-Week Range:
$18.67
$21.41
52-Week Range:
$18.67
$24.36
Beta Bionics Inc Stock (BBNX) Company Profile
Compare BBNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
21.25 | 889.87M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
140.25 | 241.69B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.09 | 153.75B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
395.87 | 150.24B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
94.32 | 120.56B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.37 | 42.42B | 5.72B | 4.17B | 490.10M | 6.97 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire
When Will Beta Bionics Reveal Its 2024 Financial Performance? Key Date Announced - StockTitan
Leerink Partnrs Comments on Beta Bionics FY2024 Earnings - Defense World
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $20.00 Average PT from Brokerages - Defense World
Kestra Medical ups IPO target to $150M - BioWorld Online
Beta Bionics initiated with a Buy at Lake Street - MSN
BofA starts coverage on insulin device maker Beta Bionics with 'buy' rating - TradingView
Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Leerink Partners - Defense World
Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Stifel Nicolaus - Defense World
BofA initiates Beta Bionics stock with Buy, sets $25 target - Investing.com India
BofA initiates Beta Bionics stock with Buy, sets $25 target By Investing.com - Investing.com South Africa
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wall Street bullish on insulin device maker Beta Bionics after IPO - TradingView
Leerink Partners sets $28 target for Beta Bionics stock By Investing.com - Investing.com South Africa
Leerink Partners sets $28 target for Beta Bionics stock - Investing.com India
Piper Sandler Initiates Beta Bionics at Overweight With $26 Price Target -February 24, 2025 at 07:15 am EST - Marketscreener.com
Stifel Initiates Beta Bionics at Buy With $25 Price Target -February 24, 2025 at 07:15 am EST - Marketscreener.com
Leerink Partners Initiates Beta Bionics at Outperform With $28 Price Target -February 24, 2025 at 07:11 am EST - Marketscreener.com
Piper Sandler sets Beta Bionics stock at overweight with $26 target By Investing.com - Investing.com South Africa
Piper Sandler sets Beta Bionics stock at overweight with $26 target - Investing.com India
Buy Recommendation for Beta Bionics: Leveraging Untapped Market Opportunities and Innovative Product Differentiation - TipRanks
Stifel initiates coverage on Beta Bionics stock with Buy rating, $25 target - Investing.com Australia
LADENBURG THALM/SH SH Begins Coverage on Beta Bionics (NASDAQ:BBNX) - MarketBeat
Stifel initiates coverage on Beta Bionics stock with Buy rating, $25 target By Investing.com - Investing.com South Africa
Beta Bionics rated new Neutral at Baird on valuation - MSN
Robert W. Baird Initiates Coverage on Beta Bionics (NASDAQ:BBNX) - Defense World
Beta Bionics (NASDAQ:BBNX) Stock Rating Upgraded by Baird R W - Defense World
Beta Bionics (NASDAQ:BBNX) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
Baird starts Beta Bionics stock with neutral, sets $20 target By Investing.com - Investing.com South Africa
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Beta Bionics stock rated new Neutral at Baird (BBNX:NASDAQ) - Seeking Alpha
Ladenburg starts Beta Bionics stock at Buy, sets $31 PT By Investing.com - Investing.com South Africa
Ladenburg starts Beta Bionics stock at Buy, sets $31 PT - Investing.com
Ladenburg Thalmann Initiates Beta Bionics at Buy With $31 Price Target -February 20, 2025 at 07:39 am EST - Marketscreener.com
Baird starts Beta Bionics stock with neutral, sets $20 target - Investing.com India
Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing - MSN
Beta Bionics (NASDAQ:BBNX) Hits New 1-Year LowShould You Sell? - MarketBeat
Beta Bionics (NASDAQ:BBNX) Trading Down 5.7%Here's Why - MarketBeat
Kestra files for $100M IPO - BioWorld Online
Beta Bionics (NASDAQ:BBNX) Sets New 12-Month Low – Time to Sell? - Defense World
Beta Bionics Debuts at Nearly $1B Value - Orange County Business Journal
Eventide Asset Management, LLC Acquires Significant Stake in Bet - GuruFocus.com
Artificial Pancreas Maker Beta Bionics Just Started Trading. Should You Buy BBNX Stock After Its IPO? - MSN
Major Shareholder Makes Bold Move with Huge Stock Purchase - TipRanks
Beta Bionics: A Sugar Rush For This IPO (NASDAQ:BBNX) - Seeking Alpha
Beta Bionics Inc Stock (BBNX) Financials Data
There is no financial data for Beta Bionics Inc (BBNX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.89%
1.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):